We're proud to receive a 2025 CDMO Leadership Award in the “Small Molecule Dosage Form - Global" category.
A pharmaceutical manufacturer established a head-to-head study comparing the safety and efficacy of Product A and Product B (the competitor’s product) for diabetic peripheral neuropathic pain (DPNP). The study was conducted in 15 countries in the EU and other countries outside the U.S. Read this case study to learn how through careful planning, the team was able to reduce the number of blister cards by 80% to just eight base cards.